Skip to main content
Premium Trial:

Request an Annual Quote

Nanogen Shares, Down 7.5 Percent, Retreat From Gains on Euro Patent News

NEW YORK, Nov. 29 (GenomeWeb News) - Shares in Nanogen slid 7.45 percent Tuesday afternoon in heavy volume after closing up more than 22 percent yesterday following news that the company's SynX subsidiary had won a European patent.

 

The stock was trading at $4.47 on the Nasdaq exchange mid-Tuesday, down from the $4.83 it reached on Monday afternoon. More than 2.4 million shares traded hands--a 285-percent increase over the average share volume for the past three months.

 

The patent, called "Method for Diagnosing and Distinguishing Stroke," covers a "diagnostic kit and method of measuring the presence of both an ischemic marker and a brain endothelial cell membrane protein to indicate that a patient has suffered a stroke and," Nanogen said in a statement. The IP is also designed to show "whether it was an ischemic or hemorrhagic cerebral event."

 

In October the US Patent and Trademark Office granted SynX a patent for "similar claims" related to the "rapid, point-of-care stoke diagnostic test that the company is developing for emergency medicine."

 

The patent covers a method and a diagnostic kit for analyzing the levels of proteins released from the brain during a neurovascular event. "By measuring the presence of an ischemic marker protein such as a myelin basic protein, S100 protein, neuronal specific enolase, or similar molecules, and a brain endothelial membrane protein such as thrombomodulin or a similar molecule, a physician can determine the occurrence of a stroke," Nanogen said.

The Scan

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.

Study Explores Animated Digital Message Approach to Communicate Genetic Test Results to Family Members

In the Journal of Genetic Counseling, the approach showed promise in participants presented with a hypothetical scenario related to a familial hereditary breast and ovarian cancer syndrome diagnosis.

Computational Tool Predicts Mammalian Messenger RNA Degradation Rates

A tool called Saluki, trained with mouse and human messenger RNA data, appears to improve mRNA half-life predictions by taking RNA and genetic features into account, a Genome Biology paper reports.

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.